» Articles » PMID: 36814039

COVID-19 and EQ-5D-5L Health State Valuation

Overview
Specialty Health Services
Date 2023 Feb 22
PMID 36814039
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We investigate whether and how general population health state values were influenced by the initial stages of the COVID-19 pandemic. Changes could have important implications, as general population values are used in health resource allocation.

Data: In Spring 2020, participants in a UK general population survey rated 2 EQ-5D-5L states, 11111 and 55555, as well as dead, using a visual analogue scale (VAS) from 100 = best imaginable health to 0 = worst imaginable health. Participants answered questions about their pandemic experiences, including COVID-19's effect on their health and quality of life, and their subjective risk/worry about infection.

Analysis: VAS ratings for 55555 were transformed to the full health = 1, dead = 0 scale. Tobit models were used to analyse VAS responses, as well as multinomial propensity score matching (MNPS) to create samples balanced according to participant characteristics.

Results: Of 3021 respondents, 2599 were used for analysis. There were statistically significant, but complex associations between experiences of COVID-19 and VAS ratings. For example, in the MNPS analysis, greater subjective risk of infection implied higher VAS ratings for dead, yet worry about infection implied lower ratings. In the Tobit analysis, people whose health was affected by COVID-19 rated 55555 higher, whether the effect on health was positive or negative.

Conclusion: The results complement previous findings that the onset of the COVID-19 pandemic may have impacted EQ-5D-5L health state valuation, and different aspects of the pandemic had different effects.

Citing Articles

The EQ-5D-5L valuation study for Trinidad and Tobago.

Bailey H, Jonker M, Pullenayegum E, Rencz F, Roudijk B Health Qual Life Outcomes. 2024; 22(1):51.

PMID: 38956543 PMC: 11218064. DOI: 10.1186/s12955-024-02266-7.


Comparison of the Measurement Properties of EQ-5D-5L and SF-6Dv2 in COVID-19 Patients in China.

Ding N, Zhou H, Chen C, Chen H, Shi Y Appl Health Econ Health Policy. 2024; 22(4):555-568.

PMID: 38641755 DOI: 10.1007/s40258-024-00881-5.

References
1.
Ovseiko P, Taylor M, Gilligan R, Birks J, Elhussein L, Rogers M . Effect of Athena SWAN funding incentives on women's research leadership. BMJ. 2020; 371:m3975. DOI: 10.1136/bmj.m3975. View

2.
Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y . Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2020; 27(1):89-95. PMC: 7510771. DOI: 10.1016/j.cmi.2020.09.023. View

3.
Troyer E, Kohn J, Hong S . Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020; 87:34-39. PMC: 7152874. DOI: 10.1016/j.bbi.2020.04.027. View

4.
Mahase E . Covid-19: Is it safe to reduce the self-isolation period?. BMJ. 2021; 375:n3164. DOI: 10.1136/bmj.n3164. View

5.
Miles D, Stedman M, Heald A . "Stay at Home, Protect the National Health Service, Save Lives": A cost benefit analysis of the lockdown in the United Kingdom. Int J Clin Pract. 2020; 75(3):e13674. PMC: 7435525. DOI: 10.1111/ijcp.13674. View